Tigecycline's patent status and subsequent patent term extensions significantly impact the availability and pricing of generic alternatives. The primary patent for tigecycline expired in December 2017 [1]. However, subsequent patent extensions and other exclusivity periods can influence when generic versions can enter the market.
When is Tigecycline Exclusivity Expected to End?
While the foundational patent for tigecycline expired in late 2017, other exclusivities and patents can delay generic entry [1]. The specific end date for all forms of market exclusivity can be complex and depend on various patent challenges and regulatory decisions.
What is the Status of Tigecycline Patents?
Tigecycline's patent landscape includes multiple patents. The expiration of the main patent in December 2017 is a key date, but other patents covering different aspects of the drug, such as manufacturing processes or specific formulations, may have later expiration dates or be subject to litigation [1][2].
How Do Patent Extensions Affect Generic Tigecycline?
Patent term extensions are designed to compensate patent holders for regulatory delays in bringing a drug to market. These extensions can push back the market exclusivity date for the branded drug, thereby delaying the entry of generic competitors [3]. For tigecycline, any granted patent term extensions on relevant patents would have pushed the exclusive marketing period beyond the initial patent expiry, directly impacting the timeline for generic approvals [1].
Can Biosimilars Enter Before Patent Expiry?
The concept of biosimilars applies to biologic drugs, while tigecycline is a small molecule antibiotic [4]. Therefore, the term "biosimilar" is not applicable here. Generic drugs, which are chemically identical to the reference product, can only enter the market after the relevant patents and exclusivity periods have expired or been successfully challenged [5].
What is the Difference Between Branded and Generic Tigecycline?
Generic tigecycline is an A-rated generic, meaning it is considered therapeutically equivalent to the branded product, Tygacil [6]. Generic versions are chemically identical and are expected to have the same dosage form, safety, strength, route of administration, quality, performance characteristics, and intended use [5]. The primary difference typically lies in the inactive ingredients and price, with generics usually being more affordable.
Who Makes Generic Tigecycline?
Multiple pharmaceutical companies are involved in the manufacturing and distribution of generic tigecycline. Some companies that have marketed or are expected to market generic tigecycline include Teva Pharmaceuticals and Hikma Pharmaceuticals [6][7].
What is the Price Difference Between Branded and Generic Tigecycline?
Generic versions of drugs are generally priced significantly lower than their branded counterparts. Following the availability of generic tigecycline, prices are expected to decrease substantially, making the treatment more accessible [5].
What Are the Clinical Data for Generic Tigecycline?
Generic tigecycline must demonstrate bioequivalence to the branded Tygacil through clinical studies [5]. This means that the generic product is absorbed into the bloodstream at the same rate and to the same extent as the reference drug. Regulatory agencies review this data to ensure the generic is safe and effective for its approved uses.
What Are Patient Concerns About Generic Tigecycline?
Patients may have concerns about the efficacy and safety of generic medications compared to branded ones. However, regulatory bodies like the U.S. Food and Drug Administration (FDA) ensure that approved generic drugs are equivalent to their brand-name counterparts [5]. The primary patient benefit of generic availability is typically reduced healthcare costs.
Where Can I Find More Information on Tigecycline Patents?
Information on tigecycline's patent status can often be found through the U.S. Food and Drug Administration's (FDA) Orange Book, which lists approved drug products with their patent and exclusivity information [8]. Patent databases and legal resources also provide detailed information on specific patent filings and litigation.
Sources:
[1] https://www.fda.gov/drugs/patent-exclusivity-patent-quarterly/patent-expiration-dates
[2] https://www.bloomberg.com/insight/research/drugs/tygacil-tigecycline-patent-and-exclusivity-data-pfizer-pfe-00005418
[3] https://www.fda.gov/drugs/development-approval-process-drugs/patent-term-restoration
[4] https://www.fda.gov/drugs/biologics/what-biosimilar-and-interchangeable-biosimilar
[5] https://www.fda.gov/drugs/generic-drugs
[6] https://www.goodrx.com/tygacil
[7] https://www.biospace.com/article/releases/hikma-announces-u-s-launch-of-generic-tigecycline-injection-60-mg-mL-vi /.
[8] https://www.fda.gov/drugs/information-on-drug-products/approved-drug-products-and-orange-book